Liminal BioSciences Inc. (LMNL)

Market Cap	10.96M
Revenue (ttm)	292,701
Net Income (ttm)	543,066
Shares Out	3.10M
EPS (ttm)	0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363
Open	3.53
Previous Close	3.53
Day's Range	3.53 - 3.53
52-Week Range	3.10 - 10.70
Beta	30.77
Analysts	Sell
Price Target	1.22 (-65.44%)
Earnings Date	May 8, 2023

About LMNL

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein c...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Bruce Pritchard BA, CA, FIOD
• Employees: 251
• Stock Exchange: NASDAQ
• Ticker Symbol: LMNL

Financial Performance

In 2022, LMNL's revenue was 401,000, a decrease of -37.64% compared to the previous year's 643,000. Earnings were 744,000, a decrease of -93.56%.

Financial numbers in CAD

Analyst Forecast

According to 6 analysts, the average rating for LMNL stock is "Sell." The 12-month stock price forecast is $1.22, which is a decrease of -65.44% from the latest price.

Price Target

$1.22

(-65.44% downside)

Analyst Consensus: Sell